Navigating the Drug Discovery Landscape: A Strategic Overview of Pharmaceutical R&D

Table of Contents

• Strategic Considerations
• Stakeholder Implications
• Overview of Pharmaceutical R&D
• Tactical Uses of High-Throughput and High-Content Technologies
  • Decreasing Cycle Times and Costs
  • Lead Identifi cation Technologies
  • Target Identifi cation and Validation Technologies
• Strategic Uses of High-Throughput and High-Content Technologies
  • Learning from Approved Drugs
    • Integrating RNA Signature Profi les with Drugs, Cellular Mechanisms, and Disease
    • Predicting Target Druggability
    • Chemical Filters
  • Predictive Toxicology
  • Patient-Specifi c Therapies
  • New Ways to Perform Clinical Trials
• Organizational and Operational Strategies
  • Team Approaches to Drug Discovery and Development
    • GlaxoSmithKline
    • Merck
    • Roche
    • Novartis
    • Wyeth
  • Information Sharing
• External Sources of Innovation
  • Academic Resources
  • Biotechnology Companies
  • Pharmaceutical Venture Capital
• Outlook for Pharmaceutical R&D

Tables

• 1. FDA-Approved Drugs Derived from Combinatorial Chemistry and/or High-Throughput Screening
• 2. Select Clinical Candidates Derived from Target Identifi cation or Validation Programs
• 3. Select Biomarkers Included in FDA-Approved Drug Labels
• 4. Comparison of Conventional and Adaptive Clinical Trials
• 5. Select Pharmaceutical Research and R&D Centers
• 6. Select Pharmaceutical Drugs Originating from Biotechnology Companies
• 7. Select Pharmaceutical/Biotechnology Venture Capital Funds

Figures

• 1. FDA New Molecular Entity Approvals, 1990-2007, vs. R&D Spending by PhRMA Members, 1990-2006
• 2. Drug Development Models: Conventional Development vs. Translation and Experimental Medicine
• 3. Comparison of Pharmaceutical R&D Structures During Discovery and Development